Efficacy of Empagliflozin Therapy in Patient with Acute Heart Failure: Meta-analysis
Abstract
Heart failure is still a common disorder with a high morbidity and mortality rate around the world. New drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin are currently showing promising results across the HF spectrum. Based on this, the authors are interested in researching the efficacy of Empaglifozin Therapy in Patient with Acute Heart Failure. This study used a systematic search using PRISMA principle in several online databases (Pubmed, Cochrane library and Google scholar). The selected study was an RCT or clinical trial with a population of Acute HF patients. The intervention group is Empagliflozin in any dose compared to placebo. The primary outcome for this meta-analysis is the levels of BNP or NT-proBNP and mortality after intervention. Selected study will be assessed and analyzed using Review Manager software version 5.3 with 95% CI. The two studies selected in this meta-analysis had a total sample size of 290 in the intervention group and 285 in the placebo group. Heterogenecity test obtained [p=0.44; I2 0%], indicating the homogenous data and the study is recommended to use the fixed effect method. The pooled effect size of RR is 0.472 [CI95% 0.24-0.75, P=0.003], meaning that there is a significant favorable outcome in empagliflozin group than in the placebo group. The results showed that empagliflozin had shown a favorable effect in reduction of the risk of death and reducing level of NT-proBNP in patient with acute heart failure.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.